Results 261 to 270 of about 87,303 (273)

CCR5 is characteristic of Th1 lymphocytes

Nature, 1998
CD4+ lymphocytes can be assigned to two subsets1. Th1 lymphocytes secrete interferon gamma (IFNγ) and lymphotoxin, promoting cell-mediated immunity to intracellular pathogens; and Th2 lymphocytes secrete interleukins 4 and 5 (IL-4 and IL-5), which function in allergy and humoral immunity to parasites.
Marco Baggiolini, Bernhard Moser, Jean-Michel Dayer, Mariagrazia Uguccioni, Pius Loetscher, Carlo Chizzolini, Lorenza Bordoli   +6 more
openaire   +2 more sources

Combinatorial synthesis of CCR5 antagonists

Bioorganic & Medicinal Chemistry Letters, 2001
Herein we report the preparation of a combinatorial library of compounds with potent CCR5 binding affinity. The library design was aided by SAR generated in a traditional medicinal chemistry effort. Compounds with novel combinations of subunits were discovered that have high binding affinity for the CCR5 receptor.
Lorraine Malkowitz, Scott C. Berk, Renee Danzeisen, Joseph Kessler, Michael W. Miller, Emilio A. Emini, William A. Schleif, Gwen Carver, Keith G. Rosauer, Janet Lineberger, Silvia Degrado, Anthony Carella, Sandra L. Gould, Karen Holmes, Daria J. Hazuda, Christopher A. Willoughby, Kevin T. Chapman, Martin S. Springer   +17 more
openaire   +2 more sources

Recent advances of CCR5 antagonists

Current Opinion in HIV and AIDS, 2006
The interaction of the beta-chemokine receptor CCR5 with the HIV-1 envelope glycoprotein gp120 is critical for viral entry. Therefore, CCR5 seems to be a promising target for inhibition of HIV-1 replication. A number of attempts have been made to identify small-molecule CCR5 antagonists as novel antiretroviral agents.
openaire   +3 more sources

Maraviroc: a new CCR5 antagonist

Expert Review of Anti-infective Therapy, 2009
Maraviroc is a small molecule and a member of a new class of antiretroviral compounds known as CCR5 antagonists, which block R5-tropic HIV entry into CD4 cells. HIV entry into the cell requires binding to a CD4 molecule and, in the majority of cases, to a coreceptor, either chemokine coreceptor 4 (CXCR4) or 5 (CCR5). In August 2007, the US FDA approved
Homayoon Khanlou, Shilpa Sayana
openaire   +3 more sources

CCR5-Maraviroc Structure

Science Signaling, 2013
The crystal structure of the HIV co-receptor CCR5 bound to the HIV drug maraviroc provides insight into how HIV enters cells.
openaire   +2 more sources

CCR5/CCR5 ligand-induced myeloid-derived suppressor cells are related to the progression of endometriosis

Reproductive BioMedicine Online, 2019
Immunological disorders have been reported to promote the progression of endometriosis. Several recent studies have shown that myeloid-derived suppressor cells (MDSC) drive the progression of endometriosis. The aim of this case-control study was to test whether CCR5 and its ligands drive MDSC accumulation and play a role in the progression of ...
Peipei Guo, Kaihuan Bi, Zhimin Lu, Kangxia Wang, Yuping Xu, Huan Wu, Yunxia Cao, Huanhuan Jiang   +7 more
openaire   +2 more sources

Identification of a Postendocytic Sorting Sequence in CCR5

Molecular Pharmacology, 2007
The chemokine receptor 5 (CCR5), a member of the G protein-coupled receptor family (GPCR), is used by human immunodeficiency virus type 1 (HIV-1) with a R5 tropism as an entry receptor in addition to CD4. It is a key target for an antiviral action aiming at inhibiting the HIV-1 entry process.
Audrey Gravot, Marc Alizon, Diana Ayinde, Anne Brelot, Maurine Delhaye, Florence Niedergang   +5 more
openaire   +3 more sources

The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection

Trends in Immunology, 2002
Abstract HIV infection is transmitted predominantly through mucosal tissues that favour strains of HIV-1 that use CCR5. A lack of cell-surface expression of CCR5 found in the homozygous Δ32 CCR5 mutation, upregulation of CC chemokines and antibodies to CCR5 are associated with resistance to HIV infection.
openaire   +4 more sources

On the dimerization of CCR5

Nature Immunology, 2005
Julie Lemay, Marc Alizon, Ralf Jockers, Anne Brelot, Stefano Marullo   +4 more
openaire   +2 more sources

The CCL5/CCR5 Axis in Cancer

2009
The multifaceted roles of chemokines and of their receptors in physiological and pathological conditions have motivated researchers to analyze their involvement also in malignant diseases. This chapter focuses on CCL5 (RANTES) and its CCR5 receptor in cancer, describing their expression patterns, activities, and roles in several malignancies. Thus far,
Adit Ben-Baruch, Gali Soria
openaire   +2 more sources